These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 25391696)
1. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. Mato-Berciano A; Morgado S; Maliandi MV; Farrera-Sal M; Gimenez-Alejandre M; Ginestà MM; Moreno R; Torres-Manjon S; Moreno P; Arias-Badia M; Rojas LA; Capellà G; Alemany R; Cascallo M; Bazan-Peregrino M J Control Release; 2021 Apr; 332():517-528. PubMed ID: 33675877 [TBL] [Abstract][Full Text] [Related]
3. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Guedan S; Rojas JJ; Gros A; Mercade E; Cascallo M; Alemany R Mol Ther; 2010 Jul; 18(7):1275-83. PubMed ID: 20442708 [TBL] [Abstract][Full Text] [Related]
4. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261 [TBL] [Abstract][Full Text] [Related]
5. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Rojas JJ; Gimenez-Alejandre M; Gil-Hoyos R; Cascallo M; Alemany R Gene Ther; 2012 Apr; 19(4):453-7. PubMed ID: 21776023 [TBL] [Abstract][Full Text] [Related]
6. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Bazan-Peregrino M; Garcia-Carbonero R; Laquente B; Álvarez R; Mato-Berciano A; Gimenez-Alejandre M; Morgado S; Rodríguez-García A; Maliandi MV; Riesco MC; Moreno R; Ginestà MM; Perez-Carreras M; Gornals JB; Prados S; Perea S; Capella G; Alemany R; Salazar R; Blasi E; Blasco C; Cascallo M; Hidalgo M J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 35149591 [TBL] [Abstract][Full Text] [Related]
7. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus. José A; Rovira-Rigau M; Luna J; Giménez-Alejandre M; Vaquero E; García de la Torre B; Andreu D; Alemany R; Fillat C J Control Release; 2014 Oct; 192():148-56. PubMed ID: 25037019 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615 [TBL] [Abstract][Full Text] [Related]
10. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393 [TBL] [Abstract][Full Text] [Related]
11. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. Yamamoto Y; Hiraoka N; Goto N; Rin Y; Miura K; Narumi K; Uchida H; Tagawa M; Aoki K J Control Release; 2014 Oct; 192():284-93. PubMed ID: 25108153 [TBL] [Abstract][Full Text] [Related]
12. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. Vera B; Martínez-Vélez N; Xipell E; Acanda de la Rocha A; Patiño-García A; Saez-Castresana J; Gonzalez-Huarriz M; Cascallo M; Alemany R; Alonso MM PLoS One; 2016; 11(1):e0147211. PubMed ID: 26808201 [TBL] [Abstract][Full Text] [Related]
14. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768 [TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104 [TBL] [Abstract][Full Text] [Related]
16. A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology. Laborda E; Puig-Saus C; Rodriguez-García A; Moreno R; Cascalló M; Pastor J; Alemany R Mol Ther; 2014 May; 22(5):986-98. PubMed ID: 24448161 [TBL] [Abstract][Full Text] [Related]
17. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063 [TBL] [Abstract][Full Text] [Related]
18. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667 [TBL] [Abstract][Full Text] [Related]
19. Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells. Bofill-De Ros X; Villanueva E; Fillat C Oncotarget; 2015 Mar; 6(8):6179-90. PubMed ID: 25714032 [TBL] [Abstract][Full Text] [Related]
20. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]